BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

？ Unified genetic and non-mutational mechanisms drive ABT-199 resistance in lymphoma ？ Rare lymphoma cells having BCL2 amplicon loss are selected during ABT-199 treatment ？ CDK7-dependent transcriptional reprogramming contributes to ABT-199 resistance ？ CDK7 inhibition prevents and overcomes ABT-199 resistance in B cell lymphoma model